Insulet

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insulet 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PODD

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. 

CEO
Ashley A. McEvoy
CEOAshley A. McEvoy
Employees
3,900
Employees3,900
Headquarters
Acton, Massachusetts
HeadquartersActon, Massachusetts
Founded
2000
Founded2000
Employees
3,900
Employees3,900

PODD Key Statistics

Market cap
20.31B
Market cap20.31B
Price-Earnings ratio
84.58
Price-Earnings ratio84.58
Dividend yield
Dividend yield
Average volume
750.84K
Average volume750.84K
High today
$297.49
High today$297.49
Low today
$287.52
Low today$287.52
Open price
$296.36
Open price$296.36
Volume
1.03M
Volume1.03M
52 Week high
$354.88
52 Week high$354.88
52 Week low
$230.05
52 Week low$230.05

Stock Snapshot

Insulet(PODD) stock is priced at $289.33, giving the company a market capitalization of 20.31B. It carries a P/E multiple of 84.58.

As of 2025-12-17, Insulet(PODD) stock has fluctuated between $287.52 and $297.49. The current price stands at $289.33, placing the stock +0.6% above today's low and -2.7% off the high.

Insulet(PODD) shares are trading with a volume of 1.03M, against a daily average of 750.84K.

In the last year, Insulet(PODD) shares hit a 52-week high of $354.88 and a 52-week low of $230.05.

In the last year, Insulet(PODD) shares hit a 52-week high of $354.88 and a 52-week low of $230.05.

PODD News

TipRanks 19h
Insulet initiated with an Outperform at Evercore ISI

Evercore ISI initiated coverage of Insulet (PODD) with an Outperform rating and $370 price target Despite new entrants, Insulet’s unique tubeless form factor is...

Simply Wall St 4d
Insulet: Valuation Check After FDA Clearance and Upbeat Earnings Growth Outlook

Insulet (PODD) just picked up FDA 510(k) clearance for a major Omnipod 5 algorithm upgrade, adding a lower 100 mg/dL glucose target and smoother automation that...

Insulet: Valuation Check After FDA Clearance and Upbeat Earnings Growth Outlook
Nasdaq 7d
Here is Why Growth Investors Should Buy Insulet Now

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional...

Here is Why Growth Investors Should Buy Insulet Now

Analyst ratings

90%

of 30 ratings
Buy
90%
Hold
10%
Sell
0%

People also own

Based on the portfolios of people who own PODD. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.